BRPI0908348A2 - Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória - Google Patents

Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória

Info

Publication number
BRPI0908348A2
BRPI0908348A2 BRPI0908348-0A BRPI0908348A BRPI0908348A2 BR PI0908348 A2 BRPI0908348 A2 BR PI0908348A2 BR PI0908348 A BRPI0908348 A BR PI0908348A BR PI0908348 A2 BRPI0908348 A2 BR PI0908348A2
Authority
BR
Brazil
Prior art keywords
kits
enhancing
compositions
methods
immune response
Prior art date
Application number
BRPI0908348-0A
Other languages
English (en)
Inventor
James Patrick Ebel
Lucy Anne Gildea
Jefrey Warren Clymer
David Alexander Lawson
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BRPI0908348A2 publication Critical patent/BRPI0908348A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0908348-0A 2008-02-06 2009-02-06 Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória BRPI0908348A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6373508P 2008-02-06 2008-02-06
PCT/US2009/033391 WO2009100331A2 (en) 2008-02-06 2009-02-06 Compositions methods and kits for enhancing immune response to a respiratory condition

Publications (1)

Publication Number Publication Date
BRPI0908348A2 true BRPI0908348A2 (pt) 2015-07-28

Family

ID=40791057

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908348-0A BRPI0908348A2 (pt) 2008-02-06 2009-02-06 Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória

Country Status (10)

Country Link
US (2) US20090196921A1 (pt)
EP (1) EP2268793A2 (pt)
JP (1) JP2011510684A (pt)
CN (1) CN101939411A (pt)
AU (1) AU2009212295A1 (pt)
BR (1) BRPI0908348A2 (pt)
CA (1) CA2713525A1 (pt)
MX (1) MX2010008720A (pt)
RU (1) RU2010132283A (pt)
WO (1) WO2009100331A2 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1622632T3 (pl) * 2003-03-21 2012-10-31 K2A Llc Suplementy diety na bazie owoców Acai oraz Jucara
BG110506A (bg) * 2009-10-27 2011-05-31 "Селур Вк Холдинг" Еоод Нови щамове млечно-кисели бактерии и техни комбинации за получаване на пробиотични препарати
IN2012DN03631A (pt) * 2009-10-30 2015-06-26 Nestec Sa
TW201121431A (en) * 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
CA2836413A1 (en) * 2010-06-01 2011-12-08 Moore Research Enterprises Llc Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
HK1253538A1 (zh) * 2010-08-04 2019-06-21 Borody Thomas J 用於糞便菌群植入的組合物及其製備和使用方法
US20120135127A1 (en) * 2010-11-29 2012-05-31 Sheng Chun Tang Pharmaceutical Industrial Co., Ltd. Dispersion having particles of ganoderma lucidum
JP5840368B2 (ja) * 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
WO2012140636A1 (en) * 2011-04-11 2012-10-18 Alimentary Health Limited A probiotic formulation
GB201110095D0 (en) * 2011-06-15 2011-07-27 Danisco Method of treatment
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
TWI481409B (zh) * 2013-01-10 2015-04-21 Conmed Pharmaceutical & Bio Medical Corp 一種使用益生菌製備用於清除尿毒素之組合物的用途
WO2014141265A1 (en) * 2013-03-14 2014-09-18 Nofar Gil Inhibition of neurodegenerative disease by grape seed extract, green tea extract and probiotic bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2014170505A2 (en) * 2013-04-19 2014-10-23 Actigenomics Sa Immunity micronutrition
WO2014195479A1 (en) * 2013-06-07 2014-12-11 Nerthus Aps Dry preparation of alpinia galanga or alpinia conchigera with high content of 1's-1'-acetoxychavicol acetate
EP3111942B1 (en) 2013-11-15 2021-01-06 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
CN103734732B (zh) * 2014-01-27 2015-08-05 杨子驿 呼吸道保健的清咽利气食品
TWI505832B (zh) 2014-02-21 2015-11-01 Genmont Biotech Inc 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途
JP6665099B2 (ja) * 2014-08-29 2020-03-13 わかもと製薬株式会社 乳酸菌含有組成物
EP3015110A1 (en) * 2014-10-28 2016-05-04 D.M.G. Italia Srl Biological barrier with cystein for the use in the treatment of naso-pharyngo-tubal infections
KR102523805B1 (ko) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 면역 조정
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
DK3206700T3 (da) 2015-06-15 2019-08-05 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
PT3240554T (pt) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
WO2017032897A1 (en) * 2015-08-27 2017-03-02 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
AU2016312624B2 (en) * 2015-08-27 2019-02-07 Alimentary Health Ltd. Bifidobacterium longum
WO2017062472A1 (en) * 2015-10-05 2017-04-13 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung injury
US20180289052A1 (en) * 2015-10-07 2018-10-11 Bifodan A/S Probiotic formulation
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR101914245B1 (ko) 2015-11-20 2018-11-02 4디 파마 리서치 리미티드 박테리아성 균주를 함유한 조성물
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA42560B1 (fr) 2016-03-04 2019-07-31 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
KR20190123267A (ko) * 2017-02-28 2019-10-31 앨러멘터리 헬스 리미티드 호흡기 바이러스 감염에 대한 면역 반응을 유익하게 조절할 수 있는 비피도박테리움 롱검
EP3589726A1 (en) 2017-02-28 2020-01-08 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
CN106978464B (zh) * 2017-04-28 2021-04-23 华南农业大学 一种提高蛹虫草Cm04类胡萝卜素产量的固体发酵方法
CN107080755A (zh) * 2017-04-28 2017-08-22 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗慢性阻塞性肺疾病制剂中的应用
TW201907928A (zh) 2017-05-22 2019-03-01 英商4D製藥研究有限公司 包含細菌品系之組成物
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201708932D0 (en) 2017-06-05 2017-07-19 Probi Ab Microbial compositions
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
EP3654990A1 (en) * 2017-06-21 2020-05-27 Ganeden Biotech, Inc. Inactivated bacillus coagulans and uses thereof for increasing physical performance
US9943503B1 (en) * 2017-10-19 2018-04-17 Edward Wick Pharmaceutical composition for treating bacterial and viral infections
JP7041272B2 (ja) * 2018-01-12 2022-03-23 ジーアイ・イノベイション・インコーポレイテッド プロバイオティクスおよびＩｇＥへの結合親和性を有するポリペプチドを含む組成物およびその使用
IT201800003804A1 (it) * 2018-03-21 2019-09-21 Neilos S R L Composizione per il trattamento delle patologie respiratorie e orofaringee
NL2021737B1 (en) * 2018-10-01 2020-05-07 Nutricia Nv Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemia
TWI713972B (zh) * 2019-01-14 2020-12-21 大江生醫股份有限公司 改善呼吸道健康之益生菌株及其組合物與用途
CN110643542B (zh) * 2019-10-25 2021-01-29 江南大学 一株可缓解变应性哮喘Th2反应的罗伊氏乳杆菌及其应用
CN110643541B (zh) * 2019-10-25 2021-08-24 江南大学 一株可调节过敏性哮喘Th2/Th1平衡的干酪乳杆菌及其应用
CA3174731A1 (en) * 2020-03-09 2022-09-07 Sofar S.P.A. Bacterial strains and compositions thereof for oral use in the treatment of viral infections of the respiratory system
IT202000005011A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso orale ad azione antivirale
US20230158089A1 (en) * 2020-04-09 2023-05-25 Chandler Biopharmaceutical Corporation Probiotic compositions and methods of use
CN116726055A (zh) * 2020-04-28 2023-09-12 香港中文大学 用于提高免疫力的组合物
CN112056399A (zh) * 2020-06-28 2020-12-11 武汉康复得生物科技股份有限公司 一种增强免疫力的益生菌组合物及其应用
US11318174B2 (en) 2020-07-09 2022-05-03 Dupont Nutrition Biosciences Aps Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
CN111743922B (zh) * 2020-07-14 2022-03-29 华熙生物科技股份有限公司 一种提高益生菌在鼻腔中的定植和活性的组合物及在鼻腔护理中的应用
US20220040228A1 (en) * 2020-08-10 2022-02-10 Frank Gaertner Materials and methods for stopping respiratory virus infections
EP4243846A2 (en) * 2020-11-12 2023-09-20 Synbiotics AB Synbiotic composition
US20220265738A1 (en) * 2021-02-12 2022-08-25 University Of South Florida Salutary effects of indigenous probiotics and nanoaerosol methods to mitigate microbial infections including covid 19
EP4297736A1 (en) * 2021-02-23 2024-01-03 Société des Produits Nestlé S.A. Composition and kit for alleviating symptoms of respiratory allergy in toddlers
TW202323517A (zh) * 2021-10-28 2023-06-16 香港中文大學 用於增強ｃｏｖｉｄ疫苗接種效力和減少來自ｃｏｖｉｄ疫苗接種的不良影響的組合物和方法
WO2023118979A1 (en) * 2021-12-22 2023-06-29 Novo Integrated Sciences Inc. System and method for antibody activators in an aqueous iodine solution
US20230217959A1 (en) * 2022-01-12 2023-07-13 Hillel Trope Dog biscuit
CN115737690B (zh) * 2022-11-11 2024-04-19 重庆医科大学 约氏乳杆菌在制备用于缓解急性呼吸窘迫综合征的药物中的应用
CN116726054B (zh) * 2022-12-05 2024-03-26 山东新时代药业有限公司 一种即食型益生菌组合物及其制备方法、用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69506550D1 (de) * 1994-07-14 1999-01-21 Du Pont Kühlzusammensetzungen
US7432097B2 (en) * 1997-08-13 2008-10-07 Verenium Corporation Phytases, nucleic acids encoding them and methods of making and using them
US20040161422A1 (en) * 1999-04-30 2004-08-19 Natarajan Ranganathan Nutritional compositions comprising probiotics
JP3633601B2 (ja) * 2001-04-27 2005-03-30 味の素株式会社 免疫賦活剤
US6764819B2 (en) * 2002-07-16 2004-07-20 Emp Biotech Gmbh Method for chemiluminescent detection
US20060263344A1 (en) * 2003-04-02 2006-11-23 Mitchell Skop Novel probiotic compositions and methods of using the same
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
WO2006048457A1 (en) * 2004-11-05 2006-05-11 Dsm Ip Assets B.V. Probiotica and polyphenol

Also Published As

Publication number Publication date
MX2010008720A (es) 2010-08-30
RU2010132283A (ru) 2012-03-20
WO2009100331A3 (en) 2009-12-17
EP2268793A2 (en) 2011-01-05
JP2011510684A (ja) 2011-04-07
CA2713525A1 (en) 2009-08-13
CN101939411A (zh) 2011-01-05
US20120114608A1 (en) 2012-05-10
US20090196921A1 (en) 2009-08-06
AU2009212295A1 (en) 2009-08-13
WO2009100331A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
BRPI0908348A2 (pt) Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória
BRPI0815407A2 (pt) Composições e métodos para controlar nematódeos
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI0917900A2 (pt) fixadores temporários
BR112012031667A2 (pt) composição
DK2634232T3 (da) Sammensætninger
BRPI0908177A2 (pt) compósito elástico e método para produzir o mesmo
BRPI0914326A2 (pt) método para formar uma corrente de oxigênio quente
DK2373293T3 (da) Sammensætninger med reduceret dimerdannelse
BR112012030304A2 (pt) método para aumentar a saúde de uma planta e uso de uma mistura
BRPI1006229A2 (pt) composição incluindo uma quantidade suficiente de curcumina
IT1392101B1 (it) Composizione comprendente isoflavoni
BR112012032683A2 (pt) composição
BRPI0913398A2 (pt) composição e métodos de adesivo para dentaduras
BRPI0917231A2 (pt) composição
BR112013014826A2 (pt) composição de gordura
FR2968670B1 (fr) Composition de graisse
BR112014009963A2 (pt) composição dietética
BR112012014028A2 (pt) uso de uma composição
BR112012032980A2 (pt) composição
BRPI0916822A2 (pt) utilização de uma composição mineral sólida
CR20130294A (es) Método in vitro para determinar la presencia de piretroides tipo ii
BRPI0917290A2 (pt) composição imunológica
BRPI0822283A2 (pt) uso de uma composição nutricional
BR112013008026A2 (pt) composições que compreendem ligantes sintéticos multivalentes de nucleolina de superfície e glicosaminaglicanos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.